A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.
Also called NCT07843485
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 600 participants
- Sponsor
- Registry
-
NCT07843485 -
2026-526189-25-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07843485. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-09 (actual); primary completion 2028-10-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
- Acronym
- ZUPREME-4
- Condition
- Obesity or Overweight
- Condition
- Type 2 Diabetes
- Intervention (Combination product)
- Petrelintide
- Intervention (Combination product)
- Placebo
- Lead sponsor
- Hoffmann-La Roche
- Collaborator
- Zealand Pharma
Record details
- Record id
cardio:ct-nct07843485- Content hash
85155c39d3a6253e2ba865eafab30edcf2ff02f61efc9d21ba3c68f14a2a9d42